

Thalomid - (50,100,150,200 mg; Capsule, Oral)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Thalidomide | Innovator | Celgene |
| Dosage | 50,100,150,200 mg; Capsule, Oral | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | Thalomid is used together with dexamethasone to treat multiple myeloma (bone marrow cancer). Thalomid is also used to treat and prevent moderate to severe skin lesions caused by leprosy. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.